UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, ~~D.C.~~DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

~~Pursuant~~Date toof ~~Section~~report ~~13 or 15~~(d)Date of ~~the~~earliest ~~Securities~~event ~~Exchange~~reported): ~~Act~~November of8, ~~1934~~2018

Date of Report: July 24, 2018

MEDICAL INNOVATION HOLDINGS, INC.

(Exact name of ~~registrant~~Registrant as specified in its charter)

Colorado	000-27211	~~000~~84-~~27211~~1469319	~~84-1469319~~
(State or other jurisdiction of Incorporation)		(Commission File Number)	(IRS Employer Identification Number)
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

5805 State Bridge Road, Suite G-328, Duluth, ~~Georgia~~GA 30097

(Address of Principal Executive Offices) ~~(Zip Code)~~

(866) 883-3793

(Registrant’'s ~~telephone~~Telephone ~~number~~Number, ~~including~~Including ~~area~~Area ~~code~~Code)

~~(Former~~ ~~name or former address, if changed since last report)~~_______________________________________________

~~Check~~(Former ~~the~~Name ~~appropriate~~or ~~box~~Former ~~below~~Address, if ~~the~~Changed ~~Form~~Since ~~8-K~~Last ~~filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:~~Report)

[Check ]the appropriate ~~Written~~box ~~communications~~below ~~pursuant~~if ~~to Rule 425 under~~ the ~~Securities~~Form ~~Act~~8-K ~~(17~~filing ~~CFR~~is ~~230.425)~~intended ~~[ ] Soliciting material pursuant~~ to ~~Rule~~simultaneously ~~14a-12~~satisfy ~~under~~ the ~~Exchange~~filing ~~Act~~obligation ~~(17~~of ~~CFR~~the ~~240.14a-12)~~registrant ~~[ ] Pre-commencement communications pursuant to Rule 14d-2(b)~~ under any of the ~~Exchange~~following ~~Act~~provisions (17see ~~CFR~~General ~~240~~Instruction A.~~14d-~~2~~(b))~~. ~~[ ] Pre-commencement communications pursuant to Rule 13e-4(c~~below) ~~under the Exchange Act (17 CFR 240.13e-4(c))~~:

~~Section~~[_] Written 1communications –pursuant ~~Registrant’s~~to ~~Business~~Rule ~~and~~425 ~~Operations~~under the Securities Act (17 CFR 230.425)

~~Item~~[_] Soliciting ~~1.02~~material ~~Termination~~pursuant ofto aRule ~~Material~~14a-12 ~~Definitive~~under ~~Agreement.~~the Exchange Act (17 CFR 240.14a-12)

~~The~~[_] Pre-commencement ~~parties~~communications ~~have~~pursuant ~~terminated~~to ~~the~~Rule ~~proposed~~14d-2(b) ~~sale~~under ~~transaction~~the ~~between~~Exchange ~~MIHI~~Act ~~and~~(17 ~~RHP~~CFR ~~as of July 9, 2018~~240.14d-2(b))

~~The~~[_] Pre-commencement ~~Agreement~~communications ~~was~~pursuant ~~for~~to ~~the~~Rule ~~sale~~13e-4(c) ~~of the assets of Seller’s business of selling supplements~~ under the ~~Revatrol®,~~Exchange ~~TBoost®, Isoprex®,~~Act ~~Prosentials®,~~(17 ~~Oraescin®,~~CFR ~~Youthful Allure™, Lexitrol Ultimate, Cerbrexum and Cerbrexum IQ™ trademarks~~240.13e-4(c))

~~The~~Indicate ~~Parties~~by ~~had~~check ~~agreed~~mark towhether ~~allocate~~ the ~~$1,000,000~~registrant ~~payment~~is asan ~~follows:~~emerging ~~$100,000~~growth ~~for~~company ~~the~~as ~~consideration~~defined ~~for~~in ~~the~~Rule ~~Non-Compete,~~405 ~~Non~~of ~~Circumvention Agreement,~~the ~~and~~Securities ~~the~~Act ~~sum~~of 1933 (§230.405 of ~~$900,000~~this ~~for~~chapter) ~~the~~or ~~purchase~~Rule 12b-2 of the ~~assets~~Securities Exchange Act of ~~RHP~~1934 (§240.12b-2 of this chapter)

~~$400,000~~Emerging ~~was~~Growth to be paid in cash at closing, and (b) payment in the amount of Four Hundred Thousand and 00/100 Dollars ($400,000.00) payable pursuant to a Convertible Promissory Note (the “Convertible Note”). The obligations of Buyer under the Convertible Note were to be secured by the Security Agreement. Seller was required to execute an intercreditor agreement with the Senior Lender in form and substance reasonably satisfactory to the Senior Lender pursuant to which the Seller shall subordinate the priority of its lien on the collateral described in the Security Agreement to the lien on such collateral arising under the Senior Loan documents.Company x

~~The~~If ~~agreement~~an ~~was~~emerging togrowth ~~purchase~~company, ~~certain~~indicate ~~assets~~by ofcheck ~~RHP~~mark ~~allowing~~if ~~MIHI~~the registrant has elected not to ~~enter~~use the ~~nutraceutical~~extended ~~market.~~transition ~~The~~period ~~Company~~for complying ~~expected~~with ~~certain cash~~any ~~flow,~~new ~~customer~~or ~~database,~~revised ~~and~~financial ~~proprietary~~accounting ~~products~~standards ~~and~~provided ~~trademarks~~pursuant to Section 13(a) of the Exchange Act. ¨

~~There~~SECTION ~~exist~~1 no– ~~relationships~~REGISTRANT’S ~~between~~BUSINESS ~~the~~AND parties other than the material definitive agreement. SELLER was RENAISSANCE HEALTH PUBLISHING, LLC, a Florida limited liability company. Buyer was MEDICAL INNOVATION HOLDINGS, INC., a Colorado corporation. The Agreement was originally signed June 27, 2017.OPERATIONS

~~The transaction~~Item ~~was~~1.01 ~~subject~~– toEntry ~~the~~into ~~Company~~a ~~raising~~Material ~~sufficient~~Definitive ~~capital to execute the transaction, which the Company was unable to complete.~~Agreement

~~There~~Settlement ~~were~~Agreement noand ~~material early termination penalties incurred by the registrant.~~Release

~~The~~On November ~~Company~~8, ~~does~~2018, ~~not~~a ~~have~~Settlement ~~any~~Agreement ~~responsibility~~and ~~for~~Release ~~termination~~(“Settlement ofAgreement”) ~~the~~was ~~agreement~~entered into by and between Medical Innovation Holdings, Inc. ~~Seller~~f/k/a ~~claims~~Medina ~~the~~International ~~company~~Holdings, ~~owes~~Inc. ~~him~~(“Company”) ~~the~~and ~~audit~~Madhava ~~results~~Rao Mankal, Daniel Medina and Harbor ~~but~~Guard ~~there~~Boats, isInc. no(“collectively ~~written~~the ~~agreement~~“Second toParties”). ~~support~~Certain ~~that~~administrative ~~assertion~~issues were not resolved until on or about November 27, 2018.

~~SIGNATURES~~The Agreement provides that Second Parties shall repossess and retain the 30 Shares of Series A Preferred Stock which were the subject of the April 29, 2016 Share Purchase Agreement which was alleged to be breached by the purchasers (collectively) due to their failure to pay certain WGCH LLC bills which resulted in a judgment against the Second Parties and the Company. The Agreement further provides for the issuance of 20 additional Series A Preferred Shares to the second parties, in consideration for the common shares which were returned to treasury by the second parties, due to the inducements in the Share Purchase Agreement referenced above, which inducements were never performed under the Share Purchase Agreement. Due to administrative delays, the stock was not issued until December 21, 2018.

~~Pursuant~~The toSettlement ~~the~~Agreement, ~~requirements~~when ofperformed under the ~~Securities~~full ~~Exchange~~terms ~~Act~~and ofcovenants ~~1934~~thereof, ~~the~~compromises, ~~Registrant~~settles ~~has~~and ~~duly~~otherwise ~~caused~~resolves ~~this~~all claims, ~~Report~~as to beany ~~signed~~unresolved onissues between Second Parties and the Company and Medhold Joint Venture (and its ~~behalf~~principals) in their byundertakings in the ~~undersigned,~~Share ~~hereunto~~Acquisition ~~duly~~and ~~authorized~~Purchase Agreement dated April 29, 2016.

MEDICAL INNOVATION HOLDINGS, INC.
By:	/s/ Arturo Jake Sanchez
Name:	Arturo “Jake” Sanchez
Date:	July 24, 2018

A copy of the Settlement Agreement and Release is attached hereto as Exhibit 10.1.

Assumption Agreement

Pursuant to the Settlement Agreement and Release referenced in the paragraphs above, an Assumption Agreement (“Assumption Agreement’) was entered into by and between Medical Innovation Holdings, Inc. (“MIHI”) and Daniel Medina, Harbor Guard Boats, Inc. and Rao Mankal (“Second Parties”).

The Assumption Agreement supplements the Settlement Agreement as to the claims and potential claims between the parties relating to WGCH, LLC judgment debt arising from or relating to the Share Purchase Agreement dated April 29, 2016. In order to induce Second Parties to accept the Settlement Agreement mentioned above, MIHI has agreed to indemnify Second Parties for 100% of the outstanding judgment of WGCH, LLC against Second Parties, including legal fees and costs and Second Parties, as consideration, have been induced to agree and have agreed to entered into a concurrent Settlement Agreement.

A copy of the Assumption Agreement is attached hereto as Exhibit 10.2.

As a result of the Settlement Agreement and Release discussed above, the Company agreed to enter into a Plan and Agreement for Reorganization which will result in a change in the ownership structure to the Company whereby at least two new businesses will be brought into the Company. The Company will contribute one business each to two new subsidiaries, which, as soon as possible, the Company shall cause to be spun off, approved and implemented within 60 days, such spin off to be completed within 120 days from November 8, 2018 (unless extended automatically due to regulatory delays), in which the first spin off subsidiary (Sub “A”) shall assume and agree to pay the convertible debt of Seshadri in the amount of approximately $100,000 with accrued interest. When the first subsidiary, Sub A, is legally spun off with all regulatory approvals for trading, Second Parties agree that they shall transfer the 50 shares of the Series A Preferred Stock of the Company to the Company by Stock Powers duly executed. The Plan and Agreement for Reorganization has not been completed and is subject to negotiations at the date hereof

The Company also agreed that under the Plan and Agreement for Reorganization referenced above, the Company shall cause to be spun off a second subsidiary (Sub “B”) for the second business contributed by the Second Parties approved and implemented within 60 days, such spin off to be completed within 120 days from November 8, 2018

(unless extended automatically due to regulatory delays), which subsidiary shall assume and agree to pay the debt to Syndicated Equity, Inc. in the approximate amount of $325,000, and the unpaid accrued legal fees to date of approximately $82,000.

SECTION 3 – SECURITIES AND TRADING MARKETS

Item 3.02 Unregistered Sales of Equity Securities

Per the Settlement Agreement and Release reported in Item 1.01 above, the Company approved the issuance of 20 shares of Series “A” Convertible Preferred Stock (Super Majority Voting) to Second Parties designee. Due to administrative delays, the stock was not issued until December 21, 2018.

The Company relied on the exemption from registration provided under Section 4(a)5 as the transactions did not involve any public offering of securities, therefore being exempt from Registration under the Securities Act of 1933.

SECTION 5 – CORPORATE GOVERNANCE AND MANAGEMENT

Item 5.01 Changes in Control of Registrant

As a result of the Settlement Agreement, the Second Parties, Daniel Medina and Madhava Rao Mankal, now own 50 shares of Series A Preferred Stock of the Company, for which the Designation of Rights and Privileges provides that each share of Series A Preferred stock votes the equivalent of 1% of the fully diluted common stock, effectively bestowing voting control – 51% - of the common stock of the Company Registrant) to the Second Parties, which when combined with the small amount of shares of common stock owned by the second parties, gives them voting control of the Company.

SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS

Item 9.01 Financial Statements and Exhibits

(d) Exhibits. The following is a complete list of exhibits filed as part of this Report. Exhibit numbers correspond to the numbers in the exhibit table of Item 601 of Regulation S-K.

Exhibit No.		Description
10.1		Settlement Agreement and Release dated November 8, 2018
10.2		Assumption Agreement dated November 8, 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Medical Innovation Holdings, Inc.

By:

_/s/ Arturo Sanchez___________________

Arturo Sanchez

Title: CEO

Date: December 24, 2018

Filing Compare · MEDICAL INNOVATION HOLDINGS, INC.